Skip to content

Longitudinal Evaluation of Silicone Hydrogel (LASH) Study

The Longitudinal Evaluation of Silicone Hydrogel (LASH) Contact Lens Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT00727402
Acronym
LASH
Enrollment
205
Registered
2008-08-04
Start date
2006-10-31
Completion date
2009-10-31
Last updated
2012-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Corneal Infiltrates

Brief summary

The LASH Contact Lens Study is a prospective longitudinal study of silicone hydrogel (SH) contact lens wearers who sleep in their lenses for up to 29 consecutive nights (30 days) of continuous wear (CW), with monthly disposal. Up to 207 healthy nearsighted or farsighted patients with minimal or no astigmatism and no contraindications to CW lens use will be followed for 1 year. The primary outcome measure is the time to development of a corneal inflammatory event (CIE) as defined by slit lamp findings and patient symptoms. The main exposure of interest is corneal staining. Other key exploratory variables include bacterial contamination of study lenses and inflammatory mediators found in the tear film.

Interventions

None listed

Sponsors

National Eye Institute (NEI)
Lead SponsorNIH

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

1. The patient must be at least 15 years old. Children younger than this may not be mature enough for CW, and may have difficulty following the strict instructions required for CW or sitting through the exam procedures. 2. The patient must have clear central corneas and free of any anterior segment disorders. 3. The patient must have a spectacle corrected spherical refractive error between +5.50 D and -11.00 D with less than or equal to 1.00 D refractive cylinder. The parameters of the Ciba Vision Night and Day Lenses range from +6.00 to -10.00 D, and can correct the refractive range of this population. Monovision correction will be allowed only if the near eye does not exceed +6.00 D. 4. The patient must be correctable to 20/25 or better with spectacles. Amblyopia will be excluded. 5. Flat and steep corneal curvatures from SimK readings must be between 39.00 and 48.00 D. Corneal curvatures outside this range may be indicative of a disease state, and patients are not expected to comfortably wear either the 8.4 mm or 8.6 mm base curve available in Night and Day.(Dumbleton K 2002) 6. Can be successfully fit with lotrafilcon A lenses at the enrollment visit.

Exclusion criteria

1. The patient has worn rigid gas permeable lenses within the last 30 days or PMMA lenses within the last 3 months. These lenses can transiently alter the corneal shape and influence the fitting of soft lenses. 2. The patient must not be a current extended wear user of lotrafilcon A lenses. 3. The patient has an autoimmune disease (except for Hashimoto's Thyroiditis), immunocompromising disease, connective tissue disease, atopic dermatitis, insulin dependent diabetes, or any other systemic disease that in the investigator's opinion will affect ocular health. 4. The patient is taking chronic systemic medications such as corticosteroids, antimetabolites, or non-steroidal anti-inflammatory agents or any other medication that in the investigator's opinion will affect ocular physiology. 5. The patient has any ocular disease or condition such as aphakia, corneal dystrophies, corneal edema, external ocular infection, iritis, or had any anterior segment surgery. 6. The patient is taking any ocular medications. 7. The patient must have less than or equal to grade 2 on any of the slit lamp observations of: upper tarsal papilla, corneal staining, corneal neovascularization, conjunctival injection, and lid erythema or scales. Slit lamp findings higher than grade 2 bias the patient toward an adverse event and it may be difficult to detect true change related to CW. 8. The patient is pregnant.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative Incidence of Corneal Inflammatory EventsannualUnadjusted cumulative incidence of corneal inflammatory events (CIE)using survival analysis methods. CIE are corneal infiltrates found in an otherwise clear cornea.

Countries

United States

Participant flow

Participants by arm

ArmCount
Observational
healthy patients fit into lotrafilcon A contact lenses for continuous wear
205
Total205

Withdrawals & dropouts

PeriodReasonFG000
Overall StudyPhysician Decision116

Baseline characteristics

CharacteristicObservational
Age Continuous32.8 years
STANDARD_DEVIATION 5
Age, Customized
<=21 years
26 participants
Age, Customized
>50 years
16 participants
Age, Customized
Between 21 and 50 years
163 participants
Region of Enrollment
United States
205 participants
Sex: Female, Male
Female
157 Participants
Sex: Female, Male
Male
48 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
— / —
other
Total, other adverse events
58 / 205
serious
Total, serious adverse events
0 / 205

Outcome results

Primary

Cumulative Incidence of Corneal Inflammatory Events

Unadjusted cumulative incidence of corneal inflammatory events (CIE)using survival analysis methods. CIE are corneal infiltrates found in an otherwise clear cornea.

Time frame: annual

ArmMeasureValue (MEAN)
ObservationalCumulative Incidence of Corneal Inflammatory Events26.7 annual incidence per 100 subjects

Source: ClinicalTrials.gov · Data processed: Mar 31, 2026